Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative Analysis of Systemic Immune Responses and Metastatic Risks in Tumor Ablation: An Animal Study of Radiofrequency Ablation and Irreversible Electroporation with Immune Modulation.
Hirata T, Sugimoto K, Soya R, Kikuchi Y, Kodama Y, Ogawa M, Nagaoka K, Sakamaki K, Itoi T, Kakimi K. Hirata T, et al. Among authors: kakimi k. Cardiovasc Intervent Radiol. 2025 Jan 9. doi: 10.1007/s00270-024-03938-z. Online ahead of print. Cardiovasc Intervent Radiol. 2025. PMID: 39789251
Immunological impact of intraperitoneal and intravenous chemotherapy in ovarian cancer, translational analyses of the Phase 3 iPocc trial.
Ogasawara A, Matsushita H, Tan TZ, Shintani D, Ye J, Nagao S, Demachi-Okamura A, Muraoka D, Kobayashi Y, Kakimi K, Yamaguchi R, Matsuo K, Yamamoto K, Fujiwara K, Huang RY, Tan DSP, Hasegawa K. Ogasawara A, et al. Among authors: kakimi k. Gynecol Oncol. 2024 Dec;191:124-131. doi: 10.1016/j.ygyno.2024.09.023. Epub 2024 Oct 15. Gynecol Oncol. 2024. PMID: 39413557 Clinical Trial.
Glioblastoma with high O6-methyl-guanine DNA methyltransferase expression are more immunologically active than tumors with low MGMT expression.
Kushihara Y, Tanaka S, Kobayashi Y, Nagaoka K, Kikuchi M, Nejo T, Yamazawa E, Nambu S, Kugasawa K, Takami H, Takayanagi S, Saito N, Kakimi K. Kushihara Y, et al. Among authors: kakimi k. Front Immunol. 2024 Jan 15;15:1328375. doi: 10.3389/fimmu.2024.1328375. eCollection 2024. Front Immunol. 2024. PMID: 38288307 Free PMC article.
Alterations in Intratumoral Immune Response before and during Early-On Nivolumab Treatment for Unresectable Advanced or Recurrent Gastric Cancer.
Sato Y, Yamashita H, Kobayashi Y, Nagaoka K, Hisayoshi T, Kawahara T, Kuroda A, Saito N, Iwata R, Okumura Y, Yagi K, Aiko S, Nomura S, Kakimi K, Seto Y. Sato Y, et al. Among authors: kakimi k. Int J Mol Sci. 2023 Nov 22;24(23):16602. doi: 10.3390/ijms242316602. Int J Mol Sci. 2023. PMID: 38068925 Free PMC article.
Immuno-genomic analysis reveals eosinophilic feature and favorable prognosis of female non-smoking esophageal squamous cell carcinomas.
Okawa Y, Sasagawa S, Kato H, Johnson TA, Nagaoka K, Kobayashi Y, Hayashi A, Shibayama T, Maejima K, Tanaka H, Miyano S, Shibahara J, Nishizuka S, Hirano S, Seto Y, Iwaya T, Kakimi K, Yasuda T, Nakagawa H. Okawa Y, et al. Among authors: kakimi k. Cancer Lett. 2024 Jan 28;581:216499. doi: 10.1016/j.canlet.2023.216499. Epub 2023 Nov 25. Cancer Lett. 2024. PMID: 38013050 Free article.
Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors.
Fujikawa K, Saito T, Kurose K, Kojima T, Funakoshi T, Sato E, Kakimi K, Iida S, Doki Y, Oka M, Ueda R, Wada H. Fujikawa K, et al. Among authors: kakimi k. PLoS One. 2023 Sep 20;18(9):e0291772. doi: 10.1371/journal.pone.0291772. eCollection 2023. PLoS One. 2023. PMID: 37729184 Free PMC article. Clinical Trial.
169 results